NCT01027351 - Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine | Biotech Hunter

Enrollment

163

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

May 31, 2012

Conditions

Meningococcal Disease

Interventions

BIOLOGICAL

Meningococcal (group B) multicomponent recombinant adsorbed vaccine.

Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB+OMV NZ) or two catch-up doses.

BIOLOGICAL

Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)

Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB).

Trial Locations (1)

Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford